Loss of bone in sickle cell trait and sickle cell disease female mice is associated with reduced igf-1 in bone and serum

Endocrinology

Volumn 157, Issue 8, 2016, Pages 3036-3046

  Xiao, Liping ^a   Andemariam, Biree ^a   Taxel, Pam ^a   Adams, Douglas J ^b   Zempsky, William T ^c   Dorcelus, Valerie ^a   Hurley, Marja M ^a,b  

^a Departmentof Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c Department of Pediatrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; DENTIN MATRIX PROTEIN 1; FERRITIN; INSULIN RECEPTOR; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PHOSPHORUS DERIVATIVE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE LEVEL; BONE MARROW DERIVED MONONUCLEAR CELL; BONE MARROW STROMA CELL; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE STRENGTH; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR DIAPHYSIS; GENE EXPRESSION; IN VITRO STUDY; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RIGIDITY; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; TIBIA; WESTERN BLOTTING; ANIMAL; BLOOD; BONE; C57BL MOUSE; CELL CULTURE; COMPLICATION; DISEASE MODEL; MALE; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SICKLE CELL TRAIT;

EID: 84982811687     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-2001     Document Type: Article

References (40)

1. Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407-412.
2. Ojodu J, Hulihan MM, Pope SN, Grant AM. Incidence of sickle cell trait-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014; 63(49):1155-1158.
3. Brinker MR, Thomas KA, Meyers SJ, et al. Bone mineral density of the lumbar spine and proximal femur is decreased in children with sickle cell anemia. Am J Orthoped. 1998;27(1):43-49.
4. Almedia A, Robert I. Bone involvement in sickle cell disease. Br J Haaematol. 2005;129:482-490.
5. Mokhtar GM, Tantaway AA, Hamed AA, Adly AA, Ismail EA, Makkeyah SM. Tartrate-resistant acid phosphatase 5b in young patients with sickle cell disease and trait siblings: relation to vasculopathy and bone mineral density. [published online ahead of print July 6, 2015]. Clin Appl Thromb Hemost. doi: 1076029615594001.
6. John N. A review of clinical profile in sickle cell traits. Oman Med J. 2010;25(1):3-8.
7. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol. 2012;87(3):340-346.
8. Neelofar MA, Archer JA, Lee E. Osteoporotic fragility fractures in African Americans: under-recognized and undertreated. J Nat Med Assoc. 2004;96(12):1640-1645.
9. Vanderjagt DJ, Bonnett C, Okolo SN, Glew RH. Assessment of the bone status of Nigerian children and adolescents with sickle cell disease using calcaneal ultrasound and serum markers of bone metabolism et al. Calcif Tiss Internat. 2002;71:133-140.
10. Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R. Bone mass mineral density in adults with sickle cell disease. Br J Haematol. 2007;136(4):666-672.
11. Voskaridou E, Stoupa E, Antoniadou L, et al. Osteoporosis and osteosclerosis in sickle cell/β-thalassemia: the role of the RANKL/ OPG axis. Haematologica. 2006;91:813- 816.
12. Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81(4):236-241.
13. Arlet JB, Courbebaisse M, Chatellier G, et al. Relationship between vitamin D deficiency and bone fragility in sickle cell disease: a cohort study of 56 adults. Bone. 2013;52:206-211.
14. Soliman AT, Bererhi H, Darwish A, Alzalabani MM, Wali Y, Ansari B. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Trop Pediatr. 1998; 44(4):194-198.
15. Luporini SM, Bendit I, Manhani R, Bracco OL, Manzella L, Giannella-Neto D. Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes. J Pediatr Hematol Oncol. 2001;23(6):357-363.
16. Canalis E. Effect of insulin-like growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest. 1980;66:709-719.
17. Mochizuki H, Hakeda Y, Wakatsuki N, et al. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology. 1992;131:1075-1080.
18. Green M, Akinsami I, Lin A, et al. Microarchitectural and mechanical characterization of the sickle bone. J. Mech Behav Biomed Mater. 2015;48:220-228.
19. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science. 1997;278(5339):873-876.
20. Homer-Bouthiette C, Doetschman T, Xiao L, Hurley MM. Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis. J Biol Chem. 2014; 289(52):36303-36314.
21. Montero A, Okada Y, Tomita M, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 2000;105(8):1085-1093.
22. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2(6):595- 610.
23. Sims NA, Clément-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095-1103.
24. Canalis E, Schilling L, Yee SP, Lee SK, Zanotti S. Hajdu Cheney mouse mutants exhibit osteopenia, increased osteoclastogenesis, and bone resorption. J Biol Chem. 2016;291(4):1538-1551.
25. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
26. Sims NA, Clément-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106(9):1095-1103.
27. Gardiner EM, Baldock PA, Thomas GP, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J. 2000; 14(13):1908-1916.
28. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporosis. Internat J Endocrinol. 2014:1-25.
29. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110: 771-781.
30. Yakar S, Courtland HW, Clemmons D. IGF-1 and bone: new discoveries from mouse models. J Bone Miner Res. 2010;25(12):2543-2552.
31. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006;47(7):901-906.
32. Ballas SK, Kesen MR, Goldberg MF, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. 2012;949535.
33. Hildebrand T, Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomechan Biomed Eng. 1997;1:15-23.
34. Sergeant G, Sergeant B. Bone and Joint lesions, Sickle Cell Disease. New York, NY: Oxford University Press; 2001;240-280.
35. Soliman AT, Bererhi H, Darwish A, Alzalabani MM, Wali Y, Ansarim B. Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. J Tropical Peds. 1998; 44:194-198.
36. Yakar S, Canalis E, Sun H, et al. Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res. 2009;24:1481-1492.
37. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002;277(46):44005-44012.
38. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Int Med. 1989;110:430- 436.
39. Weinberg ED. Iron loading: a risk factor for osteoporosis. Biometals. 2006;19:633-635.
40. Zarjou A, Jeney V, Arosio P, et al. Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res. 2010;25(1): 164-172.